Literature DB >> 7694653

Dependence of nucleic acid degradation on in situ free-radical production by adriamycin.

E Feinstein1, E Canaani, L M Weiner.   

Abstract

Adriamycin (Adr) is one of the most powerful antitumor drugs. Its therapeutic effect may be due to its cyclic reduction-oxidation and, thus, generation of oxygen radicals. Using the spin-trap 5,5'-dimethyl-1-pyrroline N-oxide (DMPO) and EPR we have demonstrated that in an enzymatic system consisting of NADPH, NADPH-cytochrome P-450 reductase, and Fe(EDTA)2 Adr stimulates formation of .OH radicals in the presence of DNA or RNA with equal efficiency. Incubation of nucleic acids in the Adr-dependent reaction generating .OH radicals resulted in extensive degradation of double- and single-stranded DNA, but did not effect RNA. In contrast, both DNA and RNA were effectively destroyed in a footprinting system, ascorbate-Fe(EDTA)2-H2O2, which generates .OH radicals in massive quantities. Fluorescence assays indicated that Adr forms stable complexes with ds- and ss-DNA but reacts only slightly with RNA. We conclude that the formation of Adr-nucleic acid complex is necessary for .OH radical-mediated cleavage of the latter, and thus, Adr may be regarded as a chemical nuclease acting in situ.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7694653     DOI: 10.1021/bi00211a026

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  14 in total

Review 1.  Avoidance of suicide in antibiotic-producing microbes.

Authors:  Eric Cundliffe; Arnold L Demain
Journal:  J Ind Microbiol Biotechnol       Date:  2010-05-06       Impact factor: 3.346

2.  The Streptomyces peucetius drrC gene encodes a UvrA-like protein involved in daunorubicin resistance and production.

Authors:  N Lomovskaya; S K Hong; S U Kim; L Fonstein; K Furuya; R C Hutchinson
Journal:  J Bacteriol       Date:  1996-06       Impact factor: 3.490

3.  Poly-ADP ribose polymerase activates nuclear proteasome to degrade oxidatively damaged histones.

Authors:  O Ullrich; T Reinheckel; N Sitte; R Hass; T Grune; K J Davies
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

4.  Synthesis and binding properties of conjugates between oligodeoxynucleotides and daunorubicin derivatives.

Authors:  A Garbesi; S Bonazzi; S Zanella; M L Capobianco; G Giannini; F Arcamone
Journal:  Nucleic Acids Res       Date:  1997-06-01       Impact factor: 16.971

5.  Role of XRCC3, XRCC1 and XPD single-nucleotide polymorphisms in survival outcomes following adjuvant chemotherapy in early stage breast cancer patients.

Authors:  E Castro; D Olmos; A Garcia; J J Cruz; R González-Sarmiento
Journal:  Clin Transl Oncol       Date:  2013-06-06       Impact factor: 3.405

6.  Methional derived from 4-methylthio-2-oxobutanoate is a cellular mediator of apoptosis in BAF3 lymphoid cells.

Authors:  G Quash; A M Roch; J Chantepie; Y Michal; G Fournet; C Dumontet
Journal:  Biochem J       Date:  1995-02-01       Impact factor: 3.857

7.  PARPi potentiates with current conventional therapy in MLL leukemia.

Authors:  Lu Zhao; Chi Wai Eric So
Journal:  Cell Cycle       Date:  2017-09-08       Impact factor: 4.534

8.  Sensitization of breast cancer cells to doxorubicin via stable cell line generation and overexpression of DFF40.

Authors:  Fatemeh Bagheri; Shahrokh Safarian; Mohamadreza Baghaban Eslaminejad; Nader Sheibani
Journal:  Biochem Cell Biol       Date:  2015-09-15       Impact factor: 3.626

9.  Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells.

Authors:  Sara Napoli; Umberto Negri; Federico Arcamone; Massimo L Capobianco; Giuseppina M Carbone; Carlo V Catapano
Journal:  Nucleic Acids Res       Date:  2006-01-30       Impact factor: 16.971

10.  Enhancing cell nucleus accumulation and DNA cleavage activity of anti-cancer drug via graphene quantum dots.

Authors:  Chong Wang; Congyu Wu; Xuejiao Zhou; Ting Han; Xiaozhen Xin; Jiaying Wu; Jingyan Zhang; Shouwu Guo
Journal:  Sci Rep       Date:  2013-10-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.